Global Oncology Academy

Early-Onset Endometrial Cancer: Bridging the Gap Between Age and Outcome
Early-Onset Endometrial Cancer: Bridging the Gap Between Age and Outcome
Project Oncology®
Early-Onset Endometrial Cancer: Bridging the Gap Between Age and Outcome
Overall Survival with Neoadjuvant Therapy in HNSCC: Examining Real-World Data
Overall Survival with Neoadjuvant Therapy in HNSCC: Examining Real-World Data
Project Oncology®
Overall Survival with Neoadjuvant Therapy in HNSCC: Examining Real-World Data
- Vanessa Helou, MD
Predicting Immunotherapy Outcomes in Head and Neck Cancer: The Role of Genetic Signatures
Predicting Immunotherapy Outcomes in Head and Neck Cancer: The Role of Genetic Signatures
Project Oncology®
Predicting Immunotherapy Outcomes in Head and Neck Cancer: The Role of Genetic Signatures
- George Laliotis, MD, MPH, MHA
Stratifying ICI-P Risk in Non-Small Cell Lung Cancer with Genetic and Radiographic Markers
Stratifying ICI-P Risk in Non-Small Cell Lung Cancer with Genetic and Radiographic Markers
Project Oncology®
Stratifying ICI-P Risk in Non-Small Cell Lung Cancer with Genetic and Radiographic Markers
Active Surveillance of Prostate Cancer: Evaluating Long-Term Outcomes
Active Surveillance of Prostate Cancer: Evaluating Long-Term Outcomes
Global Oncology Academy
Active Surveillance of Prostate Cancer: Evaluating Long-Term Outcomes
- Lisa Newcomb, PhD
Evolving Strategies in Limited-Stage Small Cell Lung Cancer Management
Evolving Strategies in Limited-Stage Small Cell Lung Cancer Management
Global Oncology Academy
Evolving Strategies in Limited-Stage Small Cell Lung Cancer Management
- Gerard A. Silvestri MD, MS, Master FCCP
- Anurag Singh, MD
- Adam H. Fox, MD, MSc
- Mariam Alexander, MD, PhD
Stratifying Advanced Endometrial Cancer: Real-World Outcomes by Molecular Subtype
Stratifying Advanced Endometrial Cancer: Real-World Outcomes by Molecular Subtype
Project Oncology®
Stratifying Advanced Endometrial Cancer: Real-World Outcomes by Molecular Subtype
Redefining mHSPC Treatment: From Monotherapy to Triplet Therapy Regimens
Redefining mHSPC Treatment: From Monotherapy to Triplet Therapy Regimens
Global Oncology Academy
Redefining mHSPC Treatment: From Monotherapy to Triplet Therapy Regimens
- Daniel J. George, MD

Medical News

Medical News
Harnessing Biobanks to Uncover Genetic Patterns in Wilms Tumors
06/04/2025
Read more
Medical News
Dietary Fiber: A Promising Intervention to Lower Multiple Myeloma Risk
06/04/2025
Read more
Medical News
Evolving Strategies to Prevent Cancer in Inflammatory Bowel Disease: Integrating Therapeutics and Surgery
06/04/2025
Read more
Medical News
Advancing Bladder Cancer Treatment: FDA's Impact on Perioperative Durvalumab and Emerging UGN-102
06/04/2025
Read more

See more news

CME/CE

Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
MinuteCE®
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
1.00 program credit
- Fortunato Ciardiello, MD, PhD
- Jenny Seligmann, MBChB, PhD
1.00 program credit
MinuteCE®
Mastering Mutation-Driven mCRC: From Testing to Targeted Therapy
1.00 credit 5 episodes
- Jenny Seligmann, MBChB, PhD
- Fortunato Ciardiello, MD, PhD
1.00 credit 5 episodes
From Guidelines to Practice: First-Line Treatment Choices in mCRC
From Guidelines to Practice: First-Line Treatment Choices in mCRC
MinuteCE®
From Guidelines to Practice: First-Line Treatment Choices in mCRC
1.00 program credit
- Fortunato Ciardiello, MD, PhD
- Jenny Seligmann, MBChB, PhD
1.00 program credit
Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
MinuteCE®
Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
1.00 program credit
- Fortunato Ciardiello, MD, PhD
- Jenny Seligmann, MBChB, PhD
1.00 program credit

Clinical Practice

TIL^plus Score as a Potential Predictive Biomarker in First-Line ICI Therapy for mccRCC
TIL^plus Score as a Potential Predictive Biomarker in First-Line ICI Therapy for mccRCC
Project Oncology®
TIL^plus Score as a Potential Predictive Biomarker in First-Line ICI Therapy for mccRCC
Understanding Extensive-Stage Small Cell Lung Cancer: Advancements and Ongoing Challenges
Understanding Extensive-Stage Small Cell Lung Cancer: Advancements and Ongoing Challenges
Global Oncology Academy
Understanding Extensive-Stage Small Cell Lung Cancer: Advancements and Ongoing Challenges
- Gerard A. Silvestri MD, MS, Master FCCP
- Anurag Singh, MD
- Adam H. Fox, MD, MSc
- Mariam Alexander, MD, PhD
Redefining Risk in Endometrial Cancer: Recurrence Prediction with Machine Learning
Redefining Risk in Endometrial Cancer: Recurrence Prediction with Machine Learning
Project Oncology®
Redefining Risk in Endometrial Cancer: Recurrence Prediction with Machine Learning
Poster Pearl: Axatilimab’s Impact on Fibrosis-Dominant Organs in cGVHD
Poster Pearl: Axatilimab’s Impact on Fibrosis-Dominant Organs in cGVHD
Project Oncology®
Poster Pearl: Axatilimab’s Impact on Fibrosis-Dominant Organs in cGVHD
- Charles Turck, PharmD, BCPS, BCCCP
- Daniel Wolff, MD

Programs

Androgen Receptor Emerges as a Marker of Differentiation in Endometrial Cancer
Androgen Receptor Emerges as a Marker of Differentiation in Endometrial Cancer
Project Oncology®
Androgen Receptor Emerges as a Marker of Differentiation in Endometrial Cancer
Personalizing Prostate Cancer Surveillance: Insights from Canary PASS
Personalizing Prostate Cancer Surveillance: Insights from Canary PASS
Global Oncology Academy
Personalizing Prostate Cancer Surveillance: Insights from Canary PASS
- Lisa Newcomb, PhD
Evolving Treatment Patterns in mHSPC: Shifts in ARPi and Triplet Use
Evolving Treatment Patterns in mHSPC: Shifts in ARPi and Triplet Use
Global Oncology Academy
Evolving Treatment Patterns in mHSPC: Shifts in ARPi and Triplet Use
- Daniel J. George, MD
Advancing Patient-Centered Care in HER2-Positive Metastatic Breast Cancer
Advancing Patient-Centered Care in HER2-Positive Metastatic Breast Cancer
Global Oncology Academy
Advancing Patient-Centered Care in HER2-Positive Metastatic Breast Cancer
- Megan Kruse, MD